Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Perianal Fistulizing Crohn's Disease (ENTERPRISE)
NCT02630966Phase 4Completed
- Sponsor
- Takeda
- Start
- Aug 2016
- Primary completion
- Sep 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 4 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Aug 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02630966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630966.